Trials / Completed
CompletedNCT04591626
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
A Randomized, Double-Blind Trial Comparing the Effect of the Addition of Dulaglutide 1.5 mg Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 291 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dulaglutide | Administered SC |
| DRUG | Placebo | Administered SC |
| DRUG | Insulin Glargine | Administered SC |
Timeline
- Start date
- 2020-12-07
- Primary completion
- 2022-04-28
- Completion
- 2022-04-28
- First posted
- 2020-10-19
- Last updated
- 2023-05-24
- Results posted
- 2023-05-24
Locations
27 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04591626. Inclusion in this directory is not an endorsement.